HighTower Advisors
BIIB icon

HighTower Advisors’s Biogen BIIB Stock Holding History

HighTower Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-100
Closed -$1K – 2611
2020
Q3 		$1K Hold
100
– – ﹤0.01% 2518
2020
Q2 		$2K Buy
+100
New +$30.1K ﹤0.01% 2377

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HighTower Advisors's BIIB Position: Q2 2026 in Review

HighTower Advisors reduced its Biogen (BIIB) stake by 5.5% in Q2 2026, selling an estimated $526K and leaving 47,099 shares worth $10.2M. The position accounts for 0.01% of the portfolio, ranked #929.

HighTower Advisors first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $11.7M in Q3 2018. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • HighTower Advisors held 47,099 shares of Biogen worth $10.2M as of Q2 2026.
  • HighTower Advisors sold 2,752 Biogen shares in Q2 2026, an estimated $526K.
  • Biogen made up 0.01% of HighTower Advisors's portfolio in Q2 2026, its #929 holding.
  • HighTower Advisors first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
  • HighTower Advisors's Biogen position peaked at $11.7M in Q3 2018.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.